Molbio Diagnostics Lists on NSE, Opens 21% Above IPO Price
· Business · Moneycontrol
Molbio Diagnostics listed on the National Stock Exchange and Bombay Stock Exchange, with shares opening 21 percent above the IPO price on its debut. The premium reflects strong investor demand for the diagnostics company’s equity. Existing shareholders can realise gains from the share price spike. The listing provides market liquidity for Molbio Diagnostics and may influence its future capital raising plans.
Why it matters
The 21 percent premium benefits institutional investors holding Molbio Diagnostics IPO shares and signals robust market appetite for the company, potentially easing its future fundraising efforts.
Read the original report — Moneycontrol
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.